AQR Capital Management LLC Sells 3,270 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

AQR Capital Management LLC decreased its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 41.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,548 shares of the biotechnology company's stock after selling 3,270 shares during the period. AQR Capital Management LLC's holdings in Axon Enterprise were worth $1,338,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of AXON. Vanguard Group Inc. boosted its holdings in Axon Enterprise by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company's stock worth $2,547,878,000 after acquiring an additional 212,401 shares during the last quarter. Motley Fool Asset Management LLC increased its stake in Axon Enterprise by 238.7% in the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company's stock valued at $153,981,000 after buying an additional 346,838 shares during the last quarter. 1832 Asset Management L.P. lifted its position in shares of Axon Enterprise by 44.0% during the 2nd quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company's stock worth $110,546,000 after buying an additional 114,800 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Axon Enterprise by 13.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company's stock worth $108,496,000 after buying an additional 45,049 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Axon Enterprise by 110.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 276,011 shares of the biotechnology company's stock valued at $71,302,000 after acquiring an additional 144,568 shares during the last quarter. Institutional investors own 79.08% of the company's stock.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $428.76 on Friday. Axon Enterprise, Inc. has a 1 year low of $199.29 and a 1 year high of $433.48. The stock has a market capitalization of $32.40 billion, a P/E ratio of 113.13, a P/E/G ratio of 11.58 and a beta of 0.94. The company's 50-day moving average is $375.57 and its 200 day moving average is $326.60. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. During the same period in the prior year, the firm earned $0.80 EPS. The company's revenue was up 34.5% compared to the same quarter last year. On average, sell-side analysts expect that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Bank of America assumed coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a "buy" rating and a $380.00 target price for the company. Jefferies Financial Group began coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a "buy" rating and a $385.00 target price for the company. Barclays lifted their price target on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an "overweight" rating in a report on Wednesday, August 7th. Craig Hallum raised their target price on Axon Enterprise from $370.00 to $376.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. Finally, Northland Securities increased their price target on Axon Enterprise from $330.00 to $365.00 and gave the stock an "outperform" rating in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $365.38.

Insider Activity

In related news, Director Matthew R. Mcbrady sold 2,000 shares of the business's stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the transaction, the director now directly owns 4,892 shares in the company, valued at $1,783,916.72. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Matthew R. Mcbrady sold 2,000 shares of the stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $364.66, for a total transaction of $729,320.00. Following the transaction, the director now owns 4,892 shares in the company, valued at $1,783,916.72. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeri Williams sold 110 shares of the business's stock in a transaction on Monday, September 30th. The shares were sold at an average price of $400.00, for a total transaction of $44,000.00. Following the sale, the director now owns 1,934 shares of the company's stock, valued at approximately $773,600. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 370,172 shares of company stock worth $136,562,182 over the last three months. 6.10% of the stock is currently owned by corporate insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.